The amount of the deal, which was part of the Series C round of the company, was not disclosed. Horizon joined Series C investors Celgene Corporation, Alexandria Real Estate Equities, and Gi Global Health Fund LP and previous backers Cambia Health Solutions, California’s Heritage Provider Network, and Japan’s Mitsui & Co. U.S. subsidiary (Mitsui USA).
The investment supports a strategic collaboration between the companies and enables further development and validation of novel, cloud-based solutions combining at the intersection of precision medicine and population health.
Led by Colin Hill, CEO and Co-founder, GNS Healthcare applies patented causal machine learning and simulation platform REFS™ (Reverse Engineering and Forward Simulation) to surface streams of patient data, such as from electronic medical records, mobile health devices, medical and pharmacy claims, genomics, consumer behavior, and more, and to match health interventions to individual patients and discover new target intervention pathways.
The company’s cloud-based solutions are used by bio-pharmaceutical companies, healthcare providers, foundations, academic medical centers, and employers.